Wockhardt Ltd announced that The Lancet Regional Health published a pivotal Phase 3 clinical study on Miqnaf (nafithromycin), a new antibiotic developed in India for treating community-acquired bacterial pneumonia, demonstrating non-inferior efficacy compared to a standard drug in nearly 500 patients.